MX354518B - Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc). - Google Patents

Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).

Info

Publication number
MX354518B
MX354518B MX2015005265A MX2015005265A MX354518B MX 354518 B MX354518 B MX 354518B MX 2015005265 A MX2015005265 A MX 2015005265A MX 2015005265 A MX2015005265 A MX 2015005265A MX 354518 B MX354518 B MX 354518B
Authority
MX
Mexico
Prior art keywords
hcc
dihydro
oxo
treatment
hepatocellular carcinoma
Prior art date
Application number
MX2015005265A
Other languages
English (en)
Other versions
MX2015005265A (es
Inventor
Bladt Friedhelm
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2015005265A publication Critical patent/MX2015005265A/es
Publication of MX354518B publication Critical patent/MX354518B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)

Abstract

3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil} -6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo o una de sus sales y/o solvatos farmacéuticamente aceptables para usar para el tratamiento de carcinoma hepatocelular (HCC).
MX2015005265A 2012-11-02 2013-10-04 Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc). MX354518B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (2)

Publication Number Publication Date
MX2015005265A MX2015005265A (es) 2015-07-17
MX354518B true MX354518B (es) 2018-03-08

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005265A MX354518B (es) 2012-11-02 2013-10-04 Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).

Country Status (26)

Country Link
US (1) US20150283137A1 (es)
EP (1) EP2914264B1 (es)
JP (1) JP6255028B2 (es)
KR (1) KR102131588B1 (es)
CN (1) CN104768553A (es)
AR (1) AR093318A1 (es)
AU (1) AU2013339823B2 (es)
BR (1) BR112015008279A2 (es)
CA (1) CA2890273C (es)
DK (1) DK2914264T3 (es)
ES (1) ES2646913T3 (es)
HK (1) HK1211869A1 (es)
HR (1) HRP20171295T1 (es)
HU (1) HUE035483T2 (es)
IL (1) IL238536B (es)
LT (1) LT2914264T (es)
MX (1) MX354518B (es)
NO (1) NO2914264T3 (es)
PL (1) PL2914264T3 (es)
PT (1) PT2914264T (es)
RS (1) RS56485B1 (es)
RU (1) RU2650679C2 (es)
SG (1) SG11201503214YA (es)
SI (1) SI2914264T1 (es)
WO (1) WO2014067610A1 (es)
ZA (1) ZA201503924B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792641A (zh) 2013-08-14 2016-07-20 有限会社日本通商 水栽培系统、和设置有水栽培系统的植物工厂以及由发泡聚苯乙烯泡沫制成的温室
KR20220034183A (ko) * 2019-07-10 2022-03-17 메르크 파텐트 게엠베하 약제학적 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA3014648C (en) * 2009-01-08 2021-06-01 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
ES2646913T3 (es) 2017-12-18
EP2914264A1 (en) 2015-09-09
PT2914264T (pt) 2017-11-14
WO2014067610A1 (en) 2014-05-08
BR112015008279A2 (pt) 2017-07-04
AU2013339823A1 (en) 2015-06-18
RU2015120692A (ru) 2016-12-27
HK1211869A1 (en) 2016-06-03
NO2914264T3 (es) 2018-01-06
AR093318A1 (es) 2015-05-27
JP2015536957A (ja) 2015-12-24
DK2914264T3 (en) 2017-09-11
KR102131588B1 (ko) 2020-07-08
HRP20171295T1 (hr) 2017-10-20
HUE035483T2 (hu) 2018-05-02
JP6255028B2 (ja) 2017-12-27
CN104768553A (zh) 2015-07-08
MX2015005265A (es) 2015-07-17
IL238536B (en) 2019-01-31
AU2013339823B2 (en) 2018-01-04
IL238536A0 (en) 2015-06-30
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
LT2914264T (lt) 2017-11-10
ZA201503924B (en) 2020-11-25
PL2914264T3 (pl) 2017-12-29
US20150283137A1 (en) 2015-10-08
RU2650679C2 (ru) 2018-04-17
EP2914264B1 (en) 2017-08-09
RS56485B1 (sr) 2018-01-31
CA2890273A1 (en) 2014-05-08
CA2890273C (en) 2021-10-26
SG11201503214YA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
DK2373640T3 (da) Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
HK1263336A1 (zh) 含有1-(3-(2-(1-苯並噻吩-5-基-)乙氧基)丙基)氮雜環丁-3-醇或其鹽的片劑
NZ627113A (en) Substituted pyrimidine compounds and their use as syk inhibitors
PH12017500718A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
MX354518B (es) Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).
NZ731770A (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
LT3408260T (lt) Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX359110B (es) Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek.
MX2022000358A (es) Preparacion farmaceutica.
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
UA88008U (en) 3-(phenoxymethyl)-5-(propylthio)-1h-1,2,4-triazole exhibiting actoprotector activity

Legal Events

Date Code Title Description
FG Grant or registration